PB1841: A NEW APPROACH IN ACUTE MYELOID LEUKEMIA (AML): SAMATYA-PREDICTING SCORE

Abstract

Background: Since it is not possible to access all methods simultaneously in determination of prognosis, it is important to use different methods together in acute myeloid leukemia (AML). Aims: We aimed to examine the efficiency for prediction of prognosis and response to induction therapy in non-APL AML cases of the “Samatya-predicting score” that we developed using clinical, cytogenetic and flow cytometric features Methods: A total of 213 patients diagnosed between January 2010-December 2020 were examined. Mortality and response to induction therapy (complete, incomplete, failure) were recorded. The subgroups were formed as follows: Responder: Complete response (CR); non-responder: Incomplete or failure. Patients who were not eligible for the study were excluded. Results: Of the 158 patients included in the study, the median value of risk score was determined as 2,5. The area under the curve for the median risk score of 2,5 in ROC analysis was 0,635 (0,541-0,729; 95% confidence interval, p=0,006) for exitus; while it was 0,605 (0,517-0,692; p=0,024) for being responder. The sensitivity for mortality was 88%, the specificity 42%, the positive predictive value (PPV) 90,1%, and the negative predictive value (NPV) was 24,7%. In terms of being non-responder to induction therapy, the sensitivity was 90,1%, the specificity 25,3%, the PPV 89,8%, and the NPV was 32%. OS was shorter in those with high risk scores. Image:Summary/Conclusion: This practical and usable scoring system we developed can be supported also by new parameters.